Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 22/11/2020
SIETES contiene 93161 citas

 1 a 20 de 162 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Savage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V, Guan J, Lam K, Luke MJ, Read SH, Stall NM, Wu W, Zhu L, Rochon PA, McCarthy LM. Evaluation of a common prescribing cascade of calcium channel blockers and diuretics in older adults with hypertension. JAMA Intern Med 2020:24 de febrero. [Ref.ID 103548]
2. Cita con resumen
Alsfouk BAA, Brodie MJ, Walters M, Kwan P, Chen Z. Tolerability of antiseizure medications in individuals with newly diagnosed epilepsy. JAMA Neurology 2020:1. [Ref.ID 103540]
3. Cita con resumen
Hripcsak G, Suchard MA, Shea S, Chen RJ, You SC, Pratt N, Madigan D, Krumholz HM, Ryan PB, Schuemie MJ. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med 2020:17 de febrero. [Ref.ID 103537]
4. Cita con resumen
Hermida RC, Crespo JJ, Domínguez-Sardina M, et al.. Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial. Eur Heart J 2019:septiembre. [Ref.ID 103201]
5.Enlace a cita original Cita con resumen
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]
6.Enlace a cita original Cita con resumen
Douros A, Dell'Aniello S, Yu OHY, Filion KB, Azoulay L, Suissa S. Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: population based cohort study. BMJ 2018;362:k2693. [Ref.ID 102821]
7.Enlace a cita original Cita con resumen
Palmer SC, Strippoli GFM. Metformin as first-line treatment for type 2 diabetes . Lancet 2018;392:14 de julio. [Ref.ID 102743]
8. Cita con resumen
9. Cita con resumen
10. Cita con resumen
Khanna R, Bressler B, Levesque BG, Zou G, Sitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, Macintosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-34. [Ref.ID 99669]
11. Cita con resumen
Stern RJ, Murphy EJ. Metformin as initial oral therapy in type 2 diabetes. JAMA 2015;313:2484-5. [Ref.ID 99310]
12. Cita con resumen
The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015;373:795-807. [Ref.ID 99275]
13.Tiene citas relacionadas Cita con resumen
Dear JW, Antoine DJ, Park BK. Where are we now with paracetamol?. BMJ 2015;351:h3705. [Ref.ID 99251]
14. Cita con resumen
Anónimo. Rethinking warfarin for atrial fibrillation. Med Lett Drugs Ther 2013;55:77. [Ref.ID 96248]
15. Cita con resumen
Anónimo. FDA approves new multiple sclerosis treatment: Tecfidera . U.S. Food and Drug Administration 2013:27 de marzo. [Ref.ID 95131]
16. Cita con resumen
Butt DA, Mamdani M, Austin PC, Tu K, Gomes T, Glazier RH. The risk of hip fracture after initiating antihypertensive drugs in the elderly. Arch Intern Med 2012;172:1739-44. [Ref.ID 94222]
18. Cita con resumen
Anónimo. Lenalidomide (Revlimid): risk of secondary primary malignancy - update. Drug Safety Update 2011;5:1-2. [Ref.ID 91625]
19. Cita con resumen
Ritchie LD, Campbell NC, Murchie P. New NICE guidelines for hypertension. BMJ 2011;343:491-2. [Ref.ID 91458]
20.Tiene citas relacionadas
Mehta SR, Eikelboom JW, Yusuf S. Double-dose clopidogrel in patients undergoing PCI for ACS. Authors' reply. Lancet 2011;377:298. [Ref.ID 90123]
Seleccionar todas
 1 a 20 de 162 siguiente >>